logo
Letters to the Editor

Blood pressure and cholesterol control in the general population. Authors' reply

Arkadiusz Niklas, Andrzej Pająk, Magdalena Kozela, Justyna Marcinkowska, Tomasz Zdrojewski, Wojciech Drygas, Aleksandra Piwońska, Wojciech Bielecki, Krystyna Kozakiewicz, Andrzej Tykarski
DOI: 10.20452/pamw.15262
Published online: March 26, 2020.
CCBYNCSACC BY-NC-SA 4.0

In this article

Authors’ reply

Introduction

We would like to thank Prof. Jankowski for his interesting comment1 to our article on blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia, published in the December issue of Polish Archives of Internal Medicine (Pol Arch Intern Med).2 Although efficacious treatment for hypertension and hypercholesterolemia is available, achieving control over these 2 modifiable risk factors is still a serious problem not only in Poland but also in most other countries as well.1,3-5 Encouraged by Prof. Jankowski, we reanalyzed data of 2037 participants of the WOBASZ II (Multicenter National Population Health Examination Survey; Polish, Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia Ludności)6 study with coexisting hypertension and hypercholesterolemia to describe an interrelation between awareness and control of these conditions.

Results

Detailed information on the awareness and control of hypertension and hypercholesterolemia is presented in Table 1. Out of 2037 people with coexisting hypertension and hypercholesterolemia, 22.1% did not know that they had lipid and blood pressure ​​above the recommended level. Out of 672 participants (33%) who were informed about having 1 of the 2 factors studied, about three‑fourth had been informed on hypertension and about one‑fourth on hypercholesterolemia. Among all participants informed about having hypertension (n = 1424), the percentage of those achieving hypertension treatment goals was higher than the percentage of persons achieving hypercholesterolemia treatment goals among 1078 participants informed about having hypercholesterolemia (39.5% and 23.3%, respectively). Out of 915 participants (30.5%) informed about having both hypertension and hypercholesterolemia, 44.3% achieved the goals of hypertension treatment, and 26.3% achieved the goals of hypercholesterolemia treatment. However, only 16.5% achieved treatment goals for both hypertension and hypercholesterolemia, and as much as 45.9% did not achieve any treatment goals. The effectiveness of treatment of the hypertension and hypercholesterolemia was higher in participants informed about having both conditions as compared with those who were informed about having only 1. In participants informed about hypertension only, the goal for hypertension treatment was achieved by 30.8%, and in participants informed about hypercholesterolemia only, the goal of hypercholesterolemia treatment was achieved by 6.1%.

Table 1. Awareness and control of hypertension and hyperlipidemia in the WOBASZ II participants with both conditions (age range, 19–99 years)
Awareness
Neither HT nor HL
HT only
HL only
HT and HL
Total
n
%
n
%
N
%
n
%
n
%
Control
Neither HT nor HL
n
450
32.7
352
25.6
153
11.1
420
30.5
1375
100
%
100
100
100
100
100
Abbreviations: HL, hypercholesterolemia; HT, hypertension
%
100
69.2
93.9
45.9
67.5
HT only
n
0
0
157
38.2
0
0
254
61.8
411
100
%
0
30.8
0
27.8
20.2
HL only
n
0
0
0
0
10
10
90
90
100
100
%
0
0
6.1
9.8
4.9
HT and HL
n
0
0
0
0
0
0
151
100
151
100
%
0
0
0
16.5
7.4
Total
n
450
22.1
509
25
163
8
915
44.9
2037
100

In the entire sample (n = 2037), both treatment goals for hypertension and hypercholesterolemia were achieved only by 7.4%. Additionally, the goal of hypertension treatment only was achieved by 20.2%, and another 4.9% achieved the goal of hypercholesterolemia treatment only. Over two‑thirds of people (67.5%) with hypertension and hypercholesterolemia did not achieve any of the 2 treatment goals.

Discussion

An alarming conclusion from our findings is that only 7.4% of persons who had coexisting hypertension and hypercholesterolemia had both of these risk factors well controlled. It is obvious that the most important cause of the poor control of hypercholesterolemia and hypertension in Poland is insufficient detection, which is followed by a combined effect of wrong prescription practices, insufficient compliance to treatment, and drug intolerance. According to our previous report, less than 15% of patients treated for hypercholesterolemia were on high or moderate doses of statins.5 Effectiveness of hypertension control seems to be better, but still, about 77% of persons with hypertension do not achieve treatment goals.4

The prevalence of coexisting HT and hypercholesterolemia in about one‑third of the general population2 and poor control of both risk factors in persons aware of having hypertension and / or hypercholesterolemia supports the recommendation to use the single‑pill combination of hypotensive and hypolipemic agents. However, it is important to remember that lifestyle modification, mainly maintaining desirable physical activity and diet, are the key factors that not only facilitate control of hypercholesterolemia and hypertension but also prevent their occurence.7

Conclusions

The example of poor control of coexisting hypercholesterolemia and hypertension calls for comprehensive national strategy of the prevention of cardiovascular disease, which would include lifestyle modification, detection of risk factors followed by an intensive efficacious intervention that would include the best available pharmacological treatments.

Author names and affiliations: Arkadiusz Niklas, Andrzej Pająk, Magdalena Kozela, Justyna Marcinkowska, Tomasz Zdrojewski, Wojciech Drygas, Aleksandra Piwońska, Wojciech Bielecki, Krystyna Kozakiewicz, Andrzej Tykarski (AN, AT: Department of Hypertension, Angiology and Internal Disease, Poznan University of Medical Science, Poznań, Poland; APa, MK: Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland; JM: Department of Computer Science and Statistics, Poznan University of Medical Science, Poznań, Poland; TZ: Department of Arterial Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland; WD, APi: Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, Institute of Cardiology, Warsaw, Poland; WD, WB: Department of Social Pathologies, Medical University of Łódz, Poland; KZ: 3rd Department of Cardiology, Medical University of Silesia, Katowice, Poland)
Conflict of interest: AP received consultation honoraria from Amgen (not directly related to the present paper).
References
  1. Jankowski P. Blood pressure and cholesterol control in the general population. Pol Arch Intern Med. 2020. 130: 258. | Crossref
  2. Niklas A, Marcinkowska J, Kozela M, et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129: 864‑873. | Crossref
  3. Tadic M, Cuspidi C. Combination of hypertension and hypercholesterolemia: do we have an adequate response? Pol Arch Inter Med. 2019; 129: 852‑854. | Crossref
  4. Niklas A, Flotyńska A, Puch‑Walczak A, et al.; WOBASZ II investigators. Prevalence, awareness, treatment and control of hypertension in the adult Polish population ‑ Multi‑center National Population Health Examination Surveys ‑ WOBASZ studies. Arch Med Sci. 2018; 14: 951‑961. | Crossref
  5. Pająk A, Szafraniec K, Polak M, et al; WOBASZ Investigators. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126: 642‑652. | Crossref